Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.


About Us



HT-001 is a topical formulation under development for the treatment of patients mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are used for treatment of cancers with EGFR up-regulation (such as non-small cell lung cancer, pancreatic cancer, breast cancer, and colon cancer). However, EGFR inhibitors are often associated with dose-limiting skin toxicities that can result in interruption of treatment. HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy.

In July 2019 Hoth entered into a Sponsored Research Agreement with the George Washington University (GW) to explore preclinical pharmacology studies with topically administered HT-001.

Development Status

HT-001 is currently in the preclinical stage of development.
Upcoming Milestones: Hoth Therapeutics submitted a request for a Pre-IND Meeting with FDA on December 22, 2020 and expects to hear back from the FDA in Q1 2021